



## VÉTOQUINOL ENTERS THE BRAZILIAN MARKET

Lure (France), June 7, 2011 – Vetoquinol announces the acquisition of 100% of the equity of Farmagricola SA in Brazil.

### **Farmagricola SA, a family-owned Brazilian company founded in 1964**

Farmagricola SA, a Sao Paulo region based company, generated revenues of around 18 million reais in 2010 (around €7.7 million), up 10% vs. previous year. Farmagricola primarily sells anti-infective and parasiticides products. Most of its revenues are generated from livestock (cattle).

The company's production plant manufactures injectable, liquid, semi-liquid and solid products and employs around 100 people. The sales network is made up of around 40 agents covering the main cattle-rearing and livestock farming regions of Brazil.

### **A strategic acquisition in the world's 2<sup>nd</sup> largest animal health market**

This acquisition establishes a foothold for Vetoquinol in the world's second-largest animal health market. Brazil is largely focused on cattle-rearing for beef production which generates the main stream of revenue. The Brazilian market grew by 7.5% in 2010 according to Vetnosis. Although cattle predominates, the market is experiencing strong growth in pets.

*"This acquisition is central to our strategy of growth through acquisition; it will enable us to continue our geographical diversification"* said Vetoquinol CEO Matthieu Frechin. *"Farmagricola brings us new growth opportunities in this key expanding market."*

### **About Vétoquinol**

Vétoquinol is an independent veterinary pharmaceutical laboratory serving both the companion and production animal markets. This family-owned group, dedicated exclusively to animal health, is the 10<sup>th</sup> largest animal healthcare laboratory in the world. More than 80% of its revenues are generated outside France.

Vétoquinol's business includes research and development, production and marketing of medicinal and non-medicinal products. Vétoquinol has positioned itself in the curative sector and has developed expertise in three therapeutic fields: anti-infectives, pain/inflammation and cardiology/nephrology.

The Group currently distributes its products in more than one hundred countries throughout Europe, North America and Asia/Pacific, with subsidiaries in 24 countries and a network of 140 distribution partners. The company has more than 1,700 employees worldwide.

**For more information:** [www.vetoquinol.com](http://www.vetoquinol.com).

**OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.**

For more information, contact:

#### **VETOQUINOL**

##### Investor relations

Marie-Josée AUBRY-ROTA

Tel.: +33 3 84 62 59 88

[relations.investisseurs@vetoquinol.com](mailto:relations.investisseurs@vetoquinol.com)

#### **KEIMA COMMUNICATION**

##### Investor relations

Emmanuel DOVERGNE

Tel.: +33 1 56 43 44 63

[emmanuel.dovergne@keima.fr](mailto:emmanuel.dovergne@keima.fr)

##### Media relations

Sibylle DESCAMPS

Tel.: +33 1 56 43 44 72

[sibylle.descamps@keima.fr](mailto:sibylle.descamps@keima.fr)